Every one of those 1 sits in a single category, gene-therapy. Of the tracked stories, 1 of 1 also mention Dr. Eric Leire, the most common co-covered peer. Genflow Biosciences Plc appears in 1 tracked Biotech story from August 8, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Genflow Biosciences Plc
Every one of those 1 sits in a single category, gene-therapy. Of the tracked stories, 1 of 1 also mention Dr. Eric Leire, the most common co-covered peer. Genflow Biosciences Plc appears in 1 tracked Biotech story from August 8, 2026. The tracked stories average 2 original sources each.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Genflow Biosciences Plc. Shared-story counts are live from our verified record — not editorial picks.
Genflow's centenarian-derived SIRT6 variant (N308K/A313S) continues to build IP protection, with a new US publication covering NAFLD/NASH and expansion into muscular diseases, underscoring the variant's pleiotropic potential in longevity and age-related conditions.